1-20 of 68
tisagenlecleucel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Cynthia Z. Qi, MBA, Xinglei Chai, PhD, Eric Q Wu
Journal: Blood
Blood (2019) 134 (Supplement_1): 4723.
DOI: https://doi.org/10.1182/blood-2019-129215
Published: 2019
Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4719.
DOI: https://doi.org/10.1182/blood-2019-122587
Published: 2019
Journal Articles

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Allison Barz Leahy, MD, Kaitlin J. Stanley, MD, Regina M. Myers, MD, Amanda M. DiNofia, MD, Lisa Wray, MD, Susan R. Rheingold, MD, Colleen Callahan, CRNP, Diane Baniewicz, CRNP, Amy E. Barry, PPCNP-BC, Maria M. Patino, BS, Stephen P. Hunger, MD, Stephan Grupp, MD PhD, David M. Barrett, Shannon L. Maude, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1464.
DOI: https://doi.org/10.1182/blood-2019-130060
Published: 2019
Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1599.
DOI: https://doi.org/10.1182/blood-2019-127490
Published: 2019
Journal Articles

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Richard J Lin, MD PhD, Stephanie M Lobaugh, MS, Martina Pennisi, Jason T Chan, RN, Yakup Batlevi, PhD, Josel D Ruiz, MPH, Theresa A Elko, MS, Molly A. Maloy, MS, Connie Lee Batlevi, MD PhD, Parastoo B. Dahi, MD, Sergio A Giralt, MD, Elena Mead, MD, Ariela Noy, MD, Maria Lia Palomba, MD, Bianca Santomasso, MD PhD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MD, Beatriz Korc-Grodzicki, MD PhD, Soo Jung Kim, NP, Mari Lynne Silverberg, Chelsea A Brooklyn, Sean M. Devlin, PhD, Miguel-Angel Perales, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1603.
DOI: https://doi.org/10.1182/blood-2019-125162
Published: 2019
Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy
Journal: Blood
Blood (2019) 134 (Supplement_1): 5308.
DOI: https://doi.org/10.1182/blood-2019-128812
Published: 2019
Journal Articles

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Anna Guidetti, MD, Giulia Perrone, MD, Paola Coluccia, MD, Luca Fumagalli, MD, Anna Dodero, MD, Lucia Farina, MD, Flavio Arienti, MD, Filippo Bagnoli, MD, Luca Pappalettera, MD, Debora Degli Innocenti, Cristiana Carniti, PhD, Daniela Codazzi, MD, Paolo Corradini
Journal: Blood
Blood (2019) 134 (Supplement_1): 5619.
DOI: https://doi.org/10.1182/blood-2019-125286
Published: 2019
Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 5598.
DOI: https://doi.org/10.1182/blood-2019-132087
Published: 2019
Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L Garfall, MD, Michael C. Milone, Lifeng Tian, PhD, Vanessa E. Gonzalez, Saar Gill, MD MRCP, FRCPath, Noelle V. Frey, MD, David M. Barrett, Marco Ruella, MD, Simon F Lacey, PhD, Jakub Svoboda, MD, Elise A. Chong, MD, Joseph A Fraietta, PhD, Megan Davis, PhD, Sunita D Nasta, MD, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Shannon L. Maude, MD PhD, Stephen J. Schuster, MD, Edward A. Stadtmauer, MD FACP, Stephan Grupp, MD PhD, David L. Porter, MD, Carl H June, MD, J. Joseph Melenhorst, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 622.
DOI: https://doi.org/10.1182/blood-2019-122513
Published: 2019
Journal Articles

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Elise A. Chong, MD, James N. Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, David L. Porter, MD, Karen Dengel, BSN, RN, Don L. Siegel, MD PhD, Joan Gilmore, BS, Stefan K. Barta, MD MRCP, MS, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 594.
DOI: https://doi.org/10.1182/blood-2019-131078
Published: 2019
Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Andrea Kuhnl, Claire Roddie, PhD MD, Nuria Martinez-Cibrian, Tobias F Menne, MD PhD FRCPath, Kim Linton, MBChB PhD, Sanne Lugthart, Sridhar Chaganti, MDPhDMRCP,FRCPath, Robin Sanderson, MRCP,FRCPath, Maria A V Marzolini, Jane Norman, MD, Wendy Osborne, MD, John Radford, Stephen Robinson, MBBS, PhD BSc, Ram Malladi, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Maeve A O'Reilly, MBBCHBAO, Muhammad Saif, MD, Geoff Shenton, Adrian Bloor, FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David A. Irvine, BSc, MBBChir, MRCP, FRCPath, PhD, Orla Stewart, Arzhang Ardavan, Kate Robinson, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Kristian M Bowles, MBBS, PhD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Rod Johnson, Andrew K McMillan, FRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 767.
DOI: https://doi.org/10.1182/blood-2019-124177
Published: 2019
Journal Articles

Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis

Adam S. Kittai, MD, Max J. Gordon, MD, Agrima Mian, MBBS, MD, Lindsey Fitzgerald, MD, Jennifer Bishop, Deborah M. Stephens, DO, Sarah J. Nagle, MD, Brian T. Hill, MD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 780.
DOI: https://doi.org/10.1182/blood-2019-124694
Published: 2019
Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1909.
DOI: https://doi.org/10.1182/blood-2019-122396
Published: 2019
Journal Articles

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Xinglei Chai, PhD, Cynthia Z. Qi, MBA, Eric Q Wu
Journal: Blood
Blood (2019) 134 (Supplement_1): 3419.
DOI: https://doi.org/10.1182/blood-2019-129070
Published: 2019
Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Alfred L. Garfall, MD, Adam D. Cohen, MD, Simon F Lacey, PhD, Lifeng Tian, PhD, Wei-Ting Hwang, PhD, Dan T. Vogl, MD, Adam Waxman, MD, Eric Lancaster, MD, Anne Marie Nelson, Regina Ferthio, Andrew Fesnak, MD, Anne Lamontagne, Andrea Brennan, Jamie Guilliams, Whitney Lynn Gladney, PhD, J. Joseph Melenhorst, PhD, Regina M Young, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Jennifer Brogdon, PhD, Randi E. Isaacs, MD, Carl H June, MD, Michael C. Milone, Edward A. Stadtmauer, MD FACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 1863.
DOI: https://doi.org/10.1182/blood-2019-131515
Published: 2019
Journal Articles

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Martina Pennisi, Miriam Sanchez-Escamilla, MD, Jessica Flynn, BS, Molly A. Maloy, MS, Mari Lynne Silverberg, Yakup Batlevi, PhD, Roni Shouval, Connie Lee Batlevi, MD PhD, Renier J. Brentjens, MD PhD, Sean M. Devlin, PhD, Parastoo B. Dahi, MD, Claudia Diamonte, RN, Sergio A Giralt, MD, Elizabeth Halton, NP-BC AOCNP, Tania Jain, MD, Elena Mead, MD, Maria Lia Palomba, MD, Bianca Santomasso, MD PhD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MD, Jae H. Park, MD, Miguel-Angel Perales, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1947.
DOI: https://doi.org/10.1182/blood-2019-126208
Published: 2019
Journal Articles

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years

Marjorie E Zettler, PhD MPH, Bruce A Feinberg, DO, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Sonam Mehta, Ajeet Gajra, MD FACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 1951.
DOI: https://doi.org/10.1182/blood-2019-127372
Published: 2019
Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 1952.
DOI: https://doi.org/10.1182/blood-2019-129593
Published: 2019
Journal Articles

Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Jonathan K. Kish, PhD MPH, Bruce A Feinberg, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 2198.
DOI: https://doi.org/10.1182/blood-2019-127741
Published: 2019
Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2199.
DOI: https://doi.org/10.1182/blood-2019-131533
Published: 2019